retatrutide clinical trial results obesity VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide trial results in 28

Clinics should also clarify who is authorized to prescribe or manage refills, often expanding roles to include NPs or PAs

These findings underscore the potential of semaglutide to be an effective treatment option, but given the broad effects, there remains a need to establish optimal dosing regimens to ensure long-term safety and efficacy for pediatric and adult patients

Sequential use with an adequate washout (both semaglutide and retatrutide have roughly week-long half-lives, so full clearance takes several weeks) is an established methodology

There is still a negative deflection for 9/12mg arms suggesting we have not reached max reduction in A1c and keep in mind this is retatrutide alone, with no other medications allowed

Individual experience only